JP2005528884A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528884A5
JP2005528884A5 JP2003536404A JP2003536404A JP2005528884A5 JP 2005528884 A5 JP2005528884 A5 JP 2005528884A5 JP 2003536404 A JP2003536404 A JP 2003536404A JP 2003536404 A JP2003536404 A JP 2003536404A JP 2005528884 A5 JP2005528884 A5 JP 2005528884A5
Authority
JP
Japan
Prior art keywords
seq
antibody
nos
host cell
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003536404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528884A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/033470 external-priority patent/WO2003033674A2/en
Publication of JP2005528884A publication Critical patent/JP2005528884A/ja
Publication of JP2005528884A5 publication Critical patent/JP2005528884A5/ja
Pending legal-status Critical Current

Links

JP2003536404A 2001-10-18 2002-10-18 Mn結合および細胞接着中和活性を有するヒト抗体 Pending JP2005528884A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34365701P 2001-10-18 2001-10-18
US37771602P 2002-05-02 2002-05-02
PCT/US2002/033470 WO2003033674A2 (en) 2001-10-18 2002-10-18 Human antibodies that have mn binding and cell adhesion-neutralizing activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010020670A Division JP2010260845A (ja) 2001-10-18 2010-02-01 Mn結合および細胞接着中和活性を有するヒト抗体

Publications (2)

Publication Number Publication Date
JP2005528884A JP2005528884A (ja) 2005-09-29
JP2005528884A5 true JP2005528884A5 (enExample) 2006-01-05

Family

ID=26993561

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003536404A Pending JP2005528884A (ja) 2001-10-18 2002-10-18 Mn結合および細胞接着中和活性を有するヒト抗体
JP2010020670A Pending JP2010260845A (ja) 2001-10-18 2010-02-01 Mn結合および細胞接着中和活性を有するヒト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010020670A Pending JP2010260845A (ja) 2001-10-18 2010-02-01 Mn結合および細胞接着中和活性を有するヒト抗体

Country Status (18)

Country Link
US (2) US7462696B2 (enExample)
EP (1) EP1438339A4 (enExample)
JP (2) JP2005528884A (enExample)
KR (1) KR20050037478A (enExample)
CN (1) CN1606569A (enExample)
AR (1) AR036833A1 (enExample)
BR (1) BR0213968A (enExample)
CA (1) CA2463943A1 (enExample)
CO (1) CO5370684A1 (enExample)
DO (1) DOP2002000494A (enExample)
HU (1) HUP0600335A2 (enExample)
IL (1) IL161411A0 (enExample)
MX (1) MXPA04003508A (enExample)
PE (1) PE20030473A1 (enExample)
PL (1) PL374304A1 (enExample)
RU (1) RU2317998C2 (enExample)
UY (1) UY27499A1 (enExample)
WO (1) WO2003033674A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191246A1 (en) * 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1664778A2 (en) * 2003-09-03 2006-06-07 Receptors LLC Nanodevices employing combinatorial artificial receptors
US7504365B2 (en) 2004-09-03 2009-03-17 Receptors Llc Combinatorial artificial receptors including tether building blocks
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
DOP2006000277A (es) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20140273033A1 (en) * 2007-04-12 2014-09-18 Universiteit Hasselt Biomarkers for multiple sclerosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
EP4001920A1 (en) * 2014-04-03 2022-05-25 AllerGenis, LLC Peptides and methods for detecting food allergy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
WO1995034650A2 (en) * 1994-06-15 1995-12-21 Ciba Corning Diagnostics Corp. Mn gene and protein
AU758957C (en) * 1998-10-23 2004-08-12 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses

Similar Documents

Publication Publication Date Title
Brandt et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population
JP2007537197A5 (enExample)
JP2020530285A5 (enExample)
JP2010511388A5 (enExample)
JP2002542798A5 (enExample)
JP2007506417A5 (enExample)
CN104086652B (zh) 抗o型口蹄疫病毒特异性单域抗体及其重组表达载体
JP2010519180A (ja) 炎症性大腸炎及び慢性膵炎の診断のために、膵臓の酵素原顆粒由来の糖タンパク質2(gp2)との免疫反応を介して体液から抗体を検出する方法
JP2009540852A5 (enExample)
RU2004115112A (ru) Антитела человека, обладающие активностью связывания c mn и нейтрализации клеточной адгезии
CN115215939A (zh) 一种融合蛋白及其制备方法与应用
US8603759B2 (en) Recombinant protein capable of binding specifically and quickly to troponin I derived from human myocardium
RU2012137304A (ru) Рекомбинантные белки для применения в вакцине, антитела к указанным белкам и диагностические и терапевтические способы, включающие указанное
EP3831449A1 (en) Tools and methods to detect and isolate colibactin producing bacteria
CN102565398B (zh) 一种华支睾吸虫病elisa诊断试剂盒
RU2004114878A (ru) Агенты, увеличивающие аффинность
CN117430709B (zh) 一种纳米抗体及其应用
US8663933B2 (en) Recombinant protein capable of binding specifically and quickly to troponin I derived from human myocardium
CN111018989A (zh) 一种抗pd-l1单克隆抗体以及在制备抗癌药物方面的应用
CN106928355B (zh) 一种CD105纳米抗体Nb184
CN106928360B (zh) 一种CD105纳米抗体Nb68
CN106928359B (zh) 一种CD105纳米抗体Nb59
Viallard et al. Glomerulonephritis caused by Actinobacillus actinomycetemcomitans mimicking c‐ANCA‐positive vasculitis
JP2005503113A5 (enExample)
CN119874915B (zh) 一种程序性死亡受体1的纳米抗体及其制备方法和应用